Related Experiment Video

Updated: Aug 15, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D

Sharon Halliburton1, Eric Herber1, Kevin M Pantalone2

  • 1Department of Pharmacy, Cleveland Clinic , Cleveland, Ohio, USA.

Endocrine Connections
|August 14, 2026
PubMed

Insights

Detecting glutamic acid decarboxylase-65 autoantibodies in type 2 diabetes patients led to reduced non-insulin antihyperglycemic use and increased insulin prescriptions. This shift impacts treatment strategies for autoimmune diabetes.

Area of Science:

  • Endocrinology
  • Immunology
  • Diabetes Mellitus Research

Background:

  • Latent Autoimmune Diabetes in Adults (LADA) management guidelines vary, with some recommending type 1 diabetes-like insulin therapy and others suggesting non-insulin agents based on C-peptide levels and comorbidities.
  • Distinguishing LADA from type 2 diabetes (T2D) is crucial for appropriate treatment, as LADA shares autoimmune characteristics with type 1 diabetes.

Purpose of the Study:

  • To investigate the effect of detecting glutamic acid decarboxylase-65 (GAD65) autoantibodies in patients initially diagnosed with type 2 diabetes on their antihyperglycemic treatment.
  • To analyze changes in the prescription of non-insulin antihyperglycemic medications and insulin following GAD65 autoantibody detection.

Main Methods:

  • Retrospective observational cohort study using electronic medical records from an academic integrated delivery network.
  • Inclusion criteria: patients diagnosed with T2D and positive GAD65 autoantibody test between September 2021 and September 2023.
  • Primary outcome: comparison of the median number of non-insulin antihyperglycemic classes at autoantibody detection and 12 months post-detection.

Main Results:

  • GAD65 autoantibody detection in T2D patients was associated with a significant decrease in the number of non-insulin antihyperglycemic classes prescribed at 12 months post-detection (median 1 to 0-1.5, P < 0.0001).
  • Fewer patients received metformin, DPP-4 inhibitors, GLP-1 RAs, SGLT2 inhibitors, sulfonylureas, and thiazolidinediones post-detection.
  • A significant increase in bolus insulin prescriptions was observed post-detection, along with a decrease in C-peptide assessments during follow-up.

Conclusions:

  • GAD65 autoantibody detection in individuals diagnosed with T2D signals a shift towards insulin therapy and away from non-insulin antihyperglycemics.
  • This finding highlights the importance of autoantibody testing for refining diabetes diagnosis and tailoring treatment, particularly in cases initially presumed to be T2D.
  • Further research is needed to understand the long-term implications of this treatment modification and the reduced monitoring of C-peptide levels.
Keywords:
C-peptideglutamic acid decarboxylase (GAD)latent autoimmune diabetes in adults (LADA)non-insulin antihyperglycemic medicationstype 2 diabetes

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...